Literature DB >> 6837655

Rapidly progressive glomerulonephritis during antituberculous therapy.

D J Hirsch, F J Bia, M Kashgarian, M J Bia.   

Abstract

Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure. Renal biopsy demonstrated lesions characteristic of rapidly progressive glomerulonephritis with minor interstitial changes. Prior reports have emphasized the tubular and interstitial lesions associated with intermittent or discontinuous rifampin therapy for tuberculosis. This report documents the occurrence of severe glomerular pathology associated with continuous, daily antituberculous therapy. The spectrum of renal lesions occurring during antituberculous therapy, particularly in association with rifampin, may be wider than previously suspected.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6837655     DOI: 10.1159/000166679

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  4 in total

1.  Resolution of hypercalcemia and acute kidney injury after treatment for pulmonary tuberculosis without the use of corticosteroids.

Authors:  Constance A A Araujo; Nicole A A Araujo; Elizabeth F Daher; José Daniel B Oliveira; Marcos Kubrusly; Pastora M A Duarte; Sonia L Silva; Sonia M H A Araujo
Journal:  Am J Trop Med Hyg       Date:  2013-01-21       Impact factor: 2.345

2.  Epithelial crescent in diabetic glomeruli. A case report.

Authors:  T Tóth
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

Review 3.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

4.  The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats.

Authors:  F Bedir; H Kocaturk; O Turangezli; E Sener; S Akyuz; F B Ozgeris; B Dabanlioglu; H Suleyman; D Altuner; B Suleyman
Journal:  Braz J Med Biol Res       Date:  2021-05-24       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.